Study #2020-0950
Incidence of severe bleeding adverse events in patients with chronic lymphocytic leukemia receiving ibrutinib in combination with direct oral anticoagulants
MD Anderson Study Status
Enrolling
Treatment Agent
Description
Incidence severe bleeding events CLL + ibrutinib + DOACs
Resources and Links
Phone Number: 1-877-MDA-6789
clinicaltrials.gov NCT No: N/A
Information and next steps
Disease:
Study phase:
Not applicable
Physician name:
Caitlin Rausch
Department:
Pharmacy Clinical Programs
For general questions about clinical trials:
1-844-794-1615
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.